Bevacizumab combined with chemotherapy in children affected by hepatocellular carcinoma: A single-center experience

Research output: Contribution to journalArticle

Abstract

Background: Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits. Patients and Methods: We report a case series of five consecutive pediatric patients with HCC who were treated with bevacizumab along with conventional platinum-based chemotherapy. Results: Overall, all five patients presented an objective response to neoadjuvant chemotherapy. Four patients remain alive and free of disease 54 months after diagnosis (range=20-85 months) after treatment with bevacizumab in combination with chemotherapy and surgery that consisted of partial liver resection in two patients and liver transplantation in three. Conclusion: In our experience, bevacizumab combined with chemotherapy was an effective and safe option for the treatment of children affected by HCC.

Original languageEnglish
Pages (from-to)1489-1493
Number of pages5
JournalAnticancer Research
Volume37
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Keywords

  • Bevacizumab
  • Childhood
  • Hepatocellular carcinoma
  • Liver transplantation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bevacizumab combined with chemotherapy in children affected by hepatocellular carcinoma: A single-center experience'. Together they form a unique fingerprint.

  • Cite this